Figure 6 from Translational Activation of ATF4 through Mitochondrial Anaplerotic Metabolic Pathways Is Required for DLBCL Growth and Survival

Figure 6 from Translational Activation of ATF4 through Mitochondrial Anaplerotic Metabolic Pathways Is Required for DLBCL Growth and Survival

<p>ATF4 translation and protein level respond to nutrient level and are regulated by autophagy. <b>A,</b> FCs of mean fluorescence intensity (MFI) of the GFP reporter expressed from the ATF4-5′UTR-GFP translation reporter in Karpas 422 cells containing control or SIRT3 shRNAs under...

Spremljeno u:

Bibliografski detalji
Glavni autor:	Meng Li (79487) (author)
Daljnji autori:	Matthew R. Teater (15129060) (author), Jun Young Hong (6588914) (author), Noel R. Park (15129063) (author), Cihangir Duy (15112006) (author), Hao Shen (195461) (author), Ling Wang (56577) (author), Zhengming Chen (385056) (author), Leandro Cerchietti (15091552) (author), Shawn M. Davidson (14911596) (author), Hening Lin (1306563) (author), Ari M. Melnick (15110132) (author)
Izdano:	2025
Teme:	Cancer Molecular and Cellular Biology Cellular Stress Responses Gene Regulation Posttranscriptional and translational control Hematological Cancers Lymphomas Metabolism
Oznake:	Dodaj oznaku Bez oznaka, Budi prvi tko označuje ovaj zapis!

Slični predmeti

Figure 1 from Translational Activation of ATF4 through Mitochondrial Anaplerotic Metabolic Pathways Is Required for DLBCL Growth and Survival
od: Meng Li (79487)
Izdano: (2025)

Figure 2 from Translational Activation of ATF4 through Mitochondrial Anaplerotic Metabolic Pathways Is Required for DLBCL Growth and Survival
od: Meng Li (79487)
Izdano: (2025)

Figure 3 from Translational Activation of ATF4 through Mitochondrial Anaplerotic Metabolic Pathways Is Required for DLBCL Growth and Survival
od: Meng Li (79487)
Izdano: (2025)

Figure 4 from Translational Activation of ATF4 through Mitochondrial Anaplerotic Metabolic Pathways Is Required for DLBCL Growth and Survival
od: Meng Li (79487)
Izdano: (2025)

Figure 5 from Translational Activation of ATF4 through Mitochondrial Anaplerotic Metabolic Pathways Is Required for DLBCL Growth and Survival
od: Meng Li (79487)
Izdano: (2025)

Figure 7 from Translational Activation of ATF4 through Mitochondrial Anaplerotic Metabolic Pathways Is Required for DLBCL Growth and Survival
od: Meng Li (79487)
Izdano: (2025)

Supplementary Table S3 from The Polyamine–Hypusine Circuit Controls an Oncogenic Translational Program Essential for Malignant Conversion in MYC-Driven Lymphoma
od: Shima Nakanishi (16336496)
Izdano: (2025)

Supplementary Table S4 from The Polyamine–Hypusine Circuit Controls an Oncogenic Translational Program Essential for Malignant Conversion in MYC-Driven Lymphoma
od: Shima Nakanishi (16336496)
Izdano: (2025)

Supplementary Tables from Molecular Evolution of Classic Hodgkin Lymphoma Revealed Through Whole-Genome Sequencing of Hodgkin and Reed Sternberg Cells
od: Francesco Maura (15022226)
Izdano: (2025)

Table S1 from The RNA m<sup>6</sup>A Reader YTHDF1 Is Required for Acute Myeloid Leukemia Progression
od: Yun-Guang Hong (14960966)
Izdano: (2025)

Table S2 from The RNA m<sup>6</sup>A Reader YTHDF1 Is Required for Acute Myeloid Leukemia Progression
od: Yun-Guang Hong (14960966)
Izdano: (2025)

Table S3 from The RNA m<sup>6</sup>A Reader YTHDF1 Is Required for Acute Myeloid Leukemia Progression
od: Yun-Guang Hong (14960966)
Izdano: (2025)

Table S4 from The RNA m<sup>6</sup>A Reader YTHDF1 Is Required for Acute Myeloid Leukemia Progression
od: Yun-Guang Hong (14960966)
Izdano: (2025)

Table S5 from The RNA m<sup>6</sup>A Reader YTHDF1 Is Required for Acute Myeloid Leukemia Progression
od: Yun-Guang Hong (14960966)
Izdano: (2025)

Table S6 from The RNA m<sup>6</sup>A Reader YTHDF1 Is Required for Acute Myeloid Leukemia Progression
od: Yun-Guang Hong (14960966)
Izdano: (2025)

Supplementary Table 1 from N-myc–Mediated Translation Control Is a Therapeutic Vulnerability in Medulloblastoma
od: Duygu Kuzuoglu-Ozturk (14960213)
Izdano: (2025)

Supplementary Table 2 from N-myc–Mediated Translation Control Is a Therapeutic Vulnerability in Medulloblastoma
od: Duygu Kuzuoglu-Ozturk (14960213)
Izdano: (2025)

Supplementary Table 3 from N-myc–Mediated Translation Control Is a Therapeutic Vulnerability in Medulloblastoma
od: Duygu Kuzuoglu-Ozturk (14960213)
Izdano: (2025)

Supplementary Tables from The IGF2BP3–COPS7B Axis Facilitates mRNA Translation to Drive Colorectal Cancer Progression
od: Jing Tang (17314958)
Izdano: (2025)

Supplementary Table S10 from CD49d Expression Identifies a Biologically Distinct Subtype of Chronic Lymphocytic Leukemia with Inferior Progression-Free Survival on BTK Inhibitor Therapy
od: Anfal Alsadhan (15907475)
Izdano: (2025)

Supplementary Table S4 from CD49d Expression Identifies a Biologically Distinct Subtype of Chronic Lymphocytic Leukemia with Inferior Progression-Free Survival on BTK Inhibitor Therapy
od: Anfal Alsadhan (15907475)
Izdano: (2025)

Supplementary Table S5 from CD49d Expression Identifies a Biologically Distinct Subtype of Chronic Lymphocytic Leukemia with Inferior Progression-Free Survival on BTK Inhibitor Therapy
od: Anfal Alsadhan (15907475)
Izdano: (2025)

Supplementary Table S6 from CD49d Expression Identifies a Biologically Distinct Subtype of Chronic Lymphocytic Leukemia with Inferior Progression-Free Survival on BTK Inhibitor Therapy
od: Anfal Alsadhan (15907475)
Izdano: (2025)

Supplementary Table S7 from CD49d Expression Identifies a Biologically Distinct Subtype of Chronic Lymphocytic Leukemia with Inferior Progression-Free Survival on BTK Inhibitor Therapy
od: Anfal Alsadhan (15907475)
Izdano: (2025)

Supplementary Table S8 from CD49d Expression Identifies a Biologically Distinct Subtype of Chronic Lymphocytic Leukemia with Inferior Progression-Free Survival on BTK Inhibitor Therapy
od: Anfal Alsadhan (15907475)
Izdano: (2025)

Supplementary Table S9 from CD49d Expression Identifies a Biologically Distinct Subtype of Chronic Lymphocytic Leukemia with Inferior Progression-Free Survival on BTK Inhibitor Therapy
od: Anfal Alsadhan (15907475)
Izdano: (2025)

Supplementary Tables from Large B-cell Lymphomas of Immune-Privileged Sites Relapse via Parallel Clonal Evolution from a Common Progenitor B Cell
od: G. Tjitske Los-de Vries (15618987)
Izdano: (2025)

Supplementary Tables S1-5 from METTL3-Mediated m<sup>6</sup>A Modification Controls Splicing Factor Abundance and Contributes to Aggressive CLL
od: Yiming Wu (15306005)
Izdano: (2025)

Supplementary Data S1 from Targeting BET Proteins Downregulates miR-33a To Promote Synergy with PIM Inhibitors in CMML
od: Christopher T. Letson (16424095)
Izdano: (2025)

Supplementary Data S2 from Targeting BET Proteins Downregulates miR-33a To Promote Synergy with PIM Inhibitors in CMML
od: Christopher T. Letson (16424095)
Izdano: (2025)

Supplementary Table S1 from Targeting BET Proteins Downregulates miR-33a To Promote Synergy with PIM Inhibitors in CMML
od: Christopher T. Letson (16424095)
Izdano: (2025)

Supplementary Table S2 from Targeting BET Proteins Downregulates miR-33a To Promote Synergy with PIM Inhibitors in CMML
od: Christopher T. Letson (16424095)
Izdano: (2025)

Supplementary Table S3 from Targeting BET Proteins Downregulates miR-33a To Promote Synergy with PIM Inhibitors in CMML
od: Christopher T. Letson (16424095)
Izdano: (2025)

Table S1 from An <i>In Vivo</i> CRISPR Screen Identifies That SNRPC Promotes Triple-Negative Breast Cancer Progression
od: Xun-Xi Lu (14952883)
Izdano: (2025)

Table S2 from An <i>In Vivo</i> CRISPR Screen Identifies That SNRPC Promotes Triple-Negative Breast Cancer Progression
od: Xun-Xi Lu (14952883)
Izdano: (2025)

Table S3 from An <i>In Vivo</i> CRISPR Screen Identifies That SNRPC Promotes Triple-Negative Breast Cancer Progression
od: Xun-Xi Lu (14952883)
Izdano: (2025)

Table S7 from An <i>In Vivo</i> CRISPR Screen Identifies That SNRPC Promotes Triple-Negative Breast Cancer Progression
od: Xun-Xi Lu (14952883)
Izdano: (2025)

Table S8 from An <i>In Vivo</i> CRISPR Screen Identifies That SNRPC Promotes Triple-Negative Breast Cancer Progression
od: Xun-Xi Lu (14952883)
Izdano: (2025)

Table S2 from MEX3A Mediates p53 Degradation to Suppress Ferroptosis and Facilitate Ovarian Cancer Tumorigenesis
od: Cheng-Kai Wang (14963880)
Izdano: (2025)

Supplementary table S5 from HDAC5 Loss Enhances Phospholipid-Derived Arachidonic Acid Generation and Confers Sensitivity to cPLA2 Inhibition in Pancreatic Cancer
od: Penglin Pan (14959703)
Izdano: (2025)

Cannot write session to /tmp/vufind_sessions/sess_9cal8pcfbsudiok0o96k6u0i8g